Since the rVSVΔG-ZEBOV-glycoprotein (GP) vaccine completed clinical trials in West Africa, over 300,000 doses of the vaccine have been deployed in response to the multiple Ebola virus disease (EVD) outbreaks in the Democratic Republic of the Congo (DRC). This evidence concerns the gene ART4 and Ebola hemorrhagic fever.